Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Gustave Roussy, Cancer Campus, Grand Paris
Repare Therapeutics
Yale University
Suzhou Zanrong Pharma Limited
Centre Leon Berard
Peter MacCallum Cancer Centre, Australia
Merck Sharp & Dohme LLC
Bridge Biotherapeutics, Inc.
University of Jena
ESSA Pharmaceuticals
Fudan University
MedPacto, Inc.
Oblato, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
EMD Serono
Affiliated Hospital of Qinghai University
Takeda
Bayer
Niguarda Hospital
Medical College of Wisconsin
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Eli Lilly and Company
Arog Pharmaceuticals, Inc.
Grupo Español de Tumores Huérfanos e Infrecuentes
TetraLogic Pharmaceuticals
Bayer
Incyte Corporation
University of Kansas Medical Center